Friday, March 17, 2017 12:39:53 PM
Even without considering NASH Fibrosis, Even without considering extension outside NASH to other liver disease etiologies, even without considering High Risk Cirrhotic compensated patients with Severe Portal Pressure, even without considering countries other than US and EU, even without considering conditions outside Liver, just considering NASH Cirrhotic decompensated patients with high MELD score (patients whose unfortunately only unlikely hope is transplant and for which no other drugs is under development other than Emricasan), you still have at least hundred thousand patients who will take what could be a
life saving therapy. This therapy could fetch as much as $100K per annum per patient similarly to target/immunotherapy cancer drugs where the risk of death is similar. That would probably mean $10B revenue pwe annum or $25B market cap (based on 20-25% avg royalties) or $1,000 PPS.
And again that is just for the NASH Cirrhosis decompensated patients in US and EU only, a tiny fraction of Emricasan addressable global market. Basically for each word 1) NASH, 2) DECOMPENSATED, 3) LIVER 4) CIRRHOTIC, 5) EU&US segment you have multiple additional addressable markets by changing and combining each one of those 5 dimensions
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM